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Abstract objective With increasing maternal antiretroviral treatment (ART), the number of children newly
infected with HIV has declined. However, the possible increased mortality in the large number of
HIV-exposed, uninfected (HEU) children may be of concern. We quantified mortality risks among
HEU children and reviewed associated factors.
methods Systematic search of electronic databases (PubMed, Scopus). We included all studies
reporting mortality of HEU children to age 60 months and associated factors. Relative risk of
mortality between HEU and HIV-unexposed, uninfected (HUU) children was extracted where
relevant. Inverse variance methods were used to adjust for study size. Random-effects models were
fitted to obtain pooled estimates.
results A total of 14 studies were included in the meta-analysis and 13 in the review of associated
factors. The pooled cumulative mortality in HEU children was 5.5% (95% CI: 4.0–7.2; I2 = 94%) at
12 months (11 studies) and 11.0% (95% CI: 7.6–15.0; I2 = 93%) at 24 months (four studies). The
pooled risk ratios for the mortality in HEU children compared to HUU children in the same setting
were 1.9 (95% CI: 0.9–3.8; I2 = 93%) at 12 months (four studies) and 2.4 (95% CI: 1.1–5.1;
I2 = 93%) at 24 months (three studies).
conclusion Compared to HUU children, mortality risk in HEU children was about double at both
age points, although the association was not statistically significant at 12 months. Interpretation of
the pooled estimates is confounded by considerable heterogeneity between studies. Further research is
needed to characterise the impact of maternal death and breastfeeding on the survival of HEU infants
in the context of maternal ART, where current evidence is limited.
keywords HIV, mortality, infant, child, risk factor, meta-analysis
Introduction
With increasing availability of lifelong antiretroviral
treatment (ART) globally, risk of mother-to-child trans-
mission (MTCT) of HIV has dramatically changed over
the past decades. When antiretroviral drugs are available
as prophylaxis, overall HIV transmission can be reduced
to <5% at cessation of breastfeeding [1]. UNAIDS
reported that many low- and middle-income countries
had achieved at least 80% coverage of services to prevent
HIV transmission to children by December 2009, with
global coverage reaching 53% [1]. In this context, the
number of children newly infected with HIV was
reported to be 220 000 [190 000–260 000] in 2014, a
48% reduction from 2002 in the highest-burden countries
[2]. The risk of MTCT has been reduced to virtually zero
in high-income countries. While serious challenges remain
in resource-limited countries to ensure better access to
and coverage of ART, elimination of MTCT is now on
the global agenda [3]. With fewer infants and children
becoming infected with HIV each year, attention has
been given to the health and survival of children born to
HIV-infected mothers who are themselves not HIV-
infected (HIV-exposed, uninfected children, hereafter
HEU children).
Studies have suggested increased mortality risks in this
group, mostly based on data from a time when antiretro-
viral drugs (ARVs) were not available [4–6]. Mortality
estimates are scarce in settings where maternal ARV or
lifetime ART is available. Different factors are associated
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with vulnerability of HEU children: (i) altered caregiving
practices when the mother was unwell or died [4]; (ii)
infant feeding practices aimed at preventing HIV trans-
mission through breastfeeding, including early weaning
and inappropriate use of breastmilk substitutes [6–8]; (iii)
increased exposure to comorbidities secondary to living
in HIV-affected households [9]; and (iv) sociodemo-
graphic and geographic factors related to the HIV status
of the mother [4]. In addition to such external and poten-
tially modifiable risk factors, inherent vulnerability of
HEU children has also been reported. Exposure to HIV is
associated with immunological alterations among HEU
children that may put them at higher risk of certain infec-
tions, especially in the absence of or with shorter breast-
feeding [10, 11]. Poor weight gain and linear growth as
well as high incidence of invasive group B streptococcal
infections among HEU children have been reported in
Europe and the United States, suggesting adverse impacts
of HIV exposure and altered immunological response in
this group [12, 13]. A study from South Africa demon-
strated that at birth, HEU infants had lower antibody
responses to certain pathogens than children born to
HIV-uninfected women (HIV-unexposed, uninfected chil-
dren, hereafter HUU children) [14].
Building on available literature, the present study aims
to analyse the risk of increased mortality among HEU
children. Given the scarcity of data reporting mortality in
HEU children vs. HUU children living in the same com-
munities with similar access to health services, we firstly
aim to generate the pooled mortality rates of HEU chil-
dren specifically. Where data are available, the pooled
relative risk of mortality of HEU children compared to
HUU children is estimated. Finally, we aim to systemati-
cally compile and describe factors, which might influence
the risk of death of HEU children to better understand
the drivers of their mortality risk.
Method
Search methods for identification of studies
Electronic searches were conducted in PubMed and Sco-
pus for studies published between 2004 and 2015 with
the following keywords: ‘HIV’; ‘Mortality’; and ‘Child’
or ‘Infant’. The search strategy used in the databases is
shown in Appendix S1. We restricted our search to stu-
dies published from 2004 for three main reasons. Firstly,
a pooled analysis was published on the same topic in
2004 which comprehensively covered the data available
at that time and reported mortality in HEU infants in
sub-Saharan Africa [15]. Secondly, ART roll-out has
began in earnest in most African settings from 2004,
which was expected to bring positive impact on both
maternal and infant survival. Finally, background mortal-
ity decreased significantly over the past decade under the
Millennium Development Goals aiming at reducing child
mortality. There were no restrictions on the type of stud-
ies. Published data from all regions were eligible. Lan-
guage was limited to English or French. Relevance of
studies was assessed by screening their title and abstract.
Retained articles were subject to full-text reviews. Refer-
ences of selected articles were screened manually to iden-
tify additional studies.
Inclusion and exclusion criteria
Studies were included if they reported mortality of infants
and/or children born to mothers who tested HIV positive
but where the infants/children themselves tested HIV nega-
tive without seroconversion during follow-up. Primary out-
come was all-cause mortality in HEU children at any time
point between birth and 60 months of age. Relative risk of
mortality between HEU and HUU children was also sought
as primary outcome when studies included HIV-unexposed
children as a control group. Studies reporting case-specific
mortality estimates were excluded. Studies not reporting
raw data were also excluded from the analysis as they did
not allow calculation of mortality estimates or relative risk
with 95% confidence interval. In certain cases, authors of
studies were contacted to obtain data. For qualitative anal-
ysis, studies were included if they reported factors associ-
ated with mortality risks of HEU children.
Statistical analysis
Primary data regarding the sample size, the number of
death and the total number of time at risk observed
(where incidence density is reported) were extracted as
raw numbers. Inverse variance methods were used to
adjust for study size, and random-effects models were fit-
ted [16]. Pooled mortality rates of HEU children at dif-
ferent time points, calculated as the number of deaths
observed divided by the number of live births, and risk
ratios of mortality between HEU and HUU children,
where available, were presented using a forest plot along
with the weight of each study in the pooled effect size.
The degree of between-study heterogeneity was assessed
using I2 statistics [17]. When high heterogeneity was
observed (I2 > 75%), the source of heterogeneity was
explored narratively by assessing exposure to factors that
can influence the risk of mortality. Sensitivity analyses
were performed to explore the effect of studies with high
risk of classification bias on the pooled estimates. The
analyses were performed with REVIEW MANAGER version
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5.3 and METAXL version 2.2. We also undertook a narra-
tive qualitative analysis on factors possibly associated
with mortality of HEU children. The quality of the
studies included in the meta-analysis was assessed using
the GRADEpro GDT (http://www.guidelinedevelop-
ment.org/).
This review was conducted in accordance with
PRISMA guidelines.
Results
Characteristics of included studies
As shown in Figure 1, 1867 articles were identified
through electronic searches, of which 59 were retained
for full-text review. A total of 35 studies were excluded
for different reasons but mainly due to absence of disag-
gregated data on children’s HIV status. Hand searches of
the reference lists of the remaining 24 articles identified
seven additional studies. Of 31 articles deemed relevant
at this stage, we finally retained 14 for meta-analysis by
excluding six articles which did not report mortality esti-
mates in HEU infants and a further 11 articles for differ-
ent reasons: one study reporting a case fatality rate for
invasive pneumococcal disease [18], one pooled analysis
[15], four studies as their mortality rates were generated
with particular inclusion criteria (e.g. conditional on sur-
vival to 9 months) [7, 19, 20, 21], one study including
children who were too old for the purpose of the study
[22], and four studies because they reported the mortality
at 4, 9 and 18 months from birth [8, 23–25]. We were
unable to make use of all the data retrieved from individ-
ual studies as they estimated mortality risks at diverse
time points. In this study, we chose the mortality esti-
mates at 3, 6, 12 and 24 months from birth as these time
points were used by most studies. The 14 included and
11 excluded articles are listed in Appendix S2. For quali-
tative analysis, we retained 13 articles with information
on associated factors.
Thirteen of the 14 studies included in the meta-analysis
were undertaken in sub-Saharan Africa, and one was con-
ducted in India. All included studies were observational
in nature: eight were nested within clinical trials [26–33]
and six were based on cohort data [4–6, 34–36]. The
majority were undertaken before the widespread use of
maternal ART. Table 1 summarises the characteristics of
the studies included in the meta-analysis.
Quality of evidence of the included studies
As shown in Table 2, we assessed the quality of evidence
in the included studies according to different outcomes.
As all studies were observational, the quality of evidence
was deemed low [37]. As for the cumulative mortality in
HEU infants at 3 months, the overall quality of six stud-
ies was downgraded to very low due to high inconsis-
tency in study results and variability in study population
in terms of access to maternal ART, breastfeeding and
infant cotrimoxazole. For the same reasons, the overall
quality of the studies that included 6-, 12- and 24-month
estimates was assessed as very low. For these three esti-
mates, downgrading was also related to the risk of classi-
fication bias in the studies of Marinda et al. [4] and Wei
et al. [35].
For the relative risk of mortality between HEU and
HUU children at both 12 and 24 months, the quality of
evidence was also downgraded to very low because of
high inconsistency in study results, the risk of classifica-
tion bias in Marinda’s study and the small number of
studies included in the generation of pooled estimates.
Mortality estimates of HEU children (Meta-analysis)
As Figure 2a shows, pooled mortality in HEU infants at
3 months of age was 2.0% [95% confidence interval
(CI): 1.5–2.7], based on 131 deaths among 5967 HEU
infants from six studies [26, 29, 33, 34]. The studies of
Becquet et al. and Kafulafula et al. show estimates from
two independent studies conducted in the same setting
with no overlaps in the study populations (Ditrame &
Ditrame Plus for Becquet et al. [34] and PEPI trial &
NVAZ trial for Kafulafula et al. [29]). The reported mor-
tality varied from 1.0% to 2.6%. A substantial difference
was observed in the duration of breastfeeding; about half
the infants in Ditrame Plus in Cote d’Ivoire had short-
term breastfeeding (a median of 4 months), whereas most
infants in NVAZ in Malawi were breastfed for longer
than 12 months. All six studies were conducted before
the availability of lifelong maternal ART. In Bork’s study
(Kesho Bora), a randomised controlled trial in Burkina
Faso, Kenya and South Africa, half of the women
received triple ARVs until breastfeeding cessation after
6 months. As indicated by the value of I2, 60% of vari-
ability between studies cannot be explained by chance.
Duration of breastfeeding might explain to a certain
extent the inconsistency in reported mortality rates; how-
ever, we were unable to undertake subgroup analyses
because the information on the median duration of
breastfeeding was not available in all studies.
Seven studies reported the mortality in HEU infants at
6 months of age [4, 6, 26, 29, 34], which differed signifi-
cantly between studies: from 2.4% in the study of Bork
et al. to 6.0% in that of Marinda et al. There was no
coverage of lifelong maternal ART when these studies
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were undertaken, except for Shapiro’s study in Botswana
where a small number of women had started maternal
ART. Half the women in Bork’s study also received 3
ARVs until cessation of breastfeeding at 6 months post-
partum. It is noteworthy that the HEU infants in included
studies had different exposures to breastfeeding both in
terms of duration and modality due to changing
recommendations on infant feeding by HIV-infected
women over time. The estimated pooled 6-month cumu-
lative mortality was 3.6% (95% CI: 2.6–4.7), based on
the data on 8940 infants with 385 deaths (Figure 2b)
with substantial heterogeneity (I2 = 84%). The study of
Records identified through database searching (n = 1867)
PubMed (n = 222)/Scopus (n = 1645)
Duplicates removed (n = 188)
Titles and abstracts screened (n = 1679)
Records excluded (n = 1620)
• No information on authors (n = 25)
• Language not English/French (n = 1)
• Articles not related to the mortality in 
HEU children (n = 1594)
Full-text articles identified as
relevant (n = 24)
Full-text articles excluded with reasons (n = 35)
• Reviews (n = 2)/Correspondence (n = 2)
• Full text not available (n = 1)
• Immunologic or hematologic analysis 
of HEU infants (n = 3)
• Focus on morbidity of HEU infants
(n = 3)
• Mortality data not disaggregated by 
HIV status of infant/child (n = 22)
• Endpoint defined as combination of 
infant HIV infection and death (n = 1)
• Time point of mortality estimate not 
clear (n = 1)
Full-text articles assessed for eligibility (n = 59)
Articles identified from reference lists
(n = 15)
Studies not included in meta-analysis (n =17)
• No mortality estimates (n = 6)
• Case fatality rate of specific disease
(n = 1)
• Pooled analysis (n = 1)
• Mortality estimates with specific 
conditions (n = 4)
• Study samples aged up to 13 years old
(n = 1) 
• Mortality estimated at time points
different from those used in the 
present study (n = 4)
Studies identified as relevant (n = 31)
Studies excluded upon
full-text review (n = 8)
No qualitative information
on associated factors
(n = 18)
Studies included in qualitative
analysis (n = 13)
Studies included in meta-analysis
(n = 14)
Figure 1 Flow diagram of study selection.
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Marinda et al. [4] seems to be the likely source of
heterogeneity, pulling the overall estimate to a higher
end. A possible explanation could be that 16% of infants
classified as ‘uninfected’ in Marinda’s study included
those who had tested negative shortly after birth but who
died subsequently without further testing. Thus, problems
associated with misclassification of HIV-infected infants
might explain the higher mortality rates. In a separate
meta-analysis excluding Marinda’s study, the pooled esti-
mate was slightly attenuated to 3.4% (95% CI: 2.9–3.9)
with significant reduction in heterogeneity (I2 = 11%)
(data not shown).
Eleven studies contributed to the summary estimate of
12–month cumulative mortality (based on 14 507 HEU
infants and 891 deaths observed by 12 months of age)
[4,28–32,34–36]. The reported mortality rates varied
considerably: the lowest estimate was 2.2% in India [32]
and the highest was 10.5% in Tanzania [35]. Figure 2c
shows the pooled mortality estimated at 5.5% (95% CI:
4.0–7.2) with extremely high heterogeneity (I2 = 94%).
The high mortality rate reported by Wei et al. [35] in
Tanzania should be understood in the context that the
HEU and HIV-indeterminate infants were grouped for
analysis, which might have caused overestimation of mor-
tality rates. We attempted to address this classification
bias by excluding the study of Wei et al. [35] and Mar-
inda et al. [4] in a separate meta-analysis, which gener-
ated a pooled estimate of 4.8% (95% CI: 3.2–6.7), but
still with high heterogeneity (I2 = 94%) (data not
shown). Other potential sources of heterogeneity could
be background infant mortality, duration of breastfeed-
ing, exposure to infant cotrimoxazole, access to maternal
ART (8% of women in Singh’s study in India) [32], and
use of short-term ART by one-third of women included
in Kourtis’s study in Malawi [30]. We were unable to
account for these factors in subgroup analyses as the nec-
essary information was not available.
Finally, we identified four studies reporting the cumula-
tive mortality in HEU infants at 24 months of age [4, 6,
27,31]. Again, the reported mortality was subject to sig-
nificant variability: 6.7% in a PMTCT trial in Botswana
[6], 9.2% in Zimbabwe [4], 13.6% in Zambia [31] and
16.0% in Tanzania [27]. As shown in Figure 2d, the
pooled cumulative mortality at 24 months was estimated
at 11.0% (95% CI: 7.6–15.0). As in the case of previous
estimates, heterogeneity among the study results was sig-
nificantly high (I2 = 93%). This high heterogeneity
remained (I2 = 93%) even after removing Marinda’s
study for the risk of bias with no significant modification
in the mortality estimate (11.6%, 95% CI: 6.8–17.6)
(data not shown).
Relative Risk of Mortality of HEU children compared to
HUU children (Meta-analysis)
As stated earlier, there are few studies comparing mortal-
ity outcome between HEU and HUU children in the same
setting. We identified four for the meta-analysis of the
overall mortality risk ratio (RR) in these two groups at
12 months of age [4, 5, 28, 36]. A total of 5995 HEU
and 13 906 HUU infants were included in the pooled
analysis. These studies were undertaken in sub-Saharan
Africa before ART was readily available for mothers. All
the HEU infants in Chilongozi’s study were given cotri-
moxazole. Information on infant feeding modalities was
available only in Rollins’s study in which the majority of
the infants received some type of breastfeeding with the
median duration of 7 months for HEU and 9 months for
Figure 2 (a) Pooled 3-month cumulative mortality in HEU infants. Note: (a) 50% short-term breastfed group (median of 4 months),
with support for replacement feeding. (b) Predominantly long-term breastfeeding (median of 8 months). (c) Breastfeeding cessation by
6 months, with support for replacement feeding. Infant cotrimoxazole. (d) Prolonged breastfeeding (>12 months). (e) Infants receiving
ARV post-exposure prophylaxis. Mortality at 100 days. Subsidized formula. (f) Majority of women ever breastfed. ART arm receiving
three ARVs from 28 to 36 weeks of pregnancy up to 6.5 months post-partum or breastfeeding cessation whichever first occurs. (b)
Pooled 6-month cumulative mortality in HEU infants. Note: (a) 50% short-term breastfed group (median of 4 months), with support
for replacement feeding. (b) Predominantly long-term breastfeeding (median of 8 months). (c) All infants were breastfed (median of
6 months). Maternal ART introduced during study. (d) Breastfeeding cessation by 6 months, with support for replacement feeding.
Infant cotrimoxazole. (e) Prolonged breastfeeding (>12 months). (f) Majority of women ever breastfed. ART arm receiving three ARVs
from 28–36 weeks of pregnancy up to 6.5 months post-partum or breastfeeding cessation whichever first occurs. (c) Pooled 12-month
cumulative mortality in HEU infants. Note: (a) 50% short-term breastfed group (median of 4 months), with support for replacement
feeding. (b) Predominantly long-term breastfeeding (median of 8 months). (c) Cotrimoxazole given to all infants. (d) Breastfeeding ces-
sation by 6 months, with support for replacement feeding. Infant cotrimoxazole. (e) Prolonged breastfeeding (> 12 months). (f) All
women breastfeeding with a half weaning at 4 months. Infants received weaning supplement and cotrimoxazole. (g) 8% of mothers
with maternal ART. (h) Women randomized to receive triple ARVs until cessation of breastfeeding. Majority weaned at 6 months.
Cotrimoxazole given to all infants. (i) Majority of infants received some type of breastfeeding (median of 7 months). (d) Pooled 24-
month cumulative mortality in HEU children. Note: (a) All infants were breastfed (median of 6 months). Maternal ART introduced
during study. (b) All women breastfeeding with a half weaning at 4 months. Children received cotrimoxazole.
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Figure 3 (a) Mortality risk ratio at 12 months between HEU and HUU infants. (b) Mortality risk ratio at 12 months between HEU
and HUU infants (excluding Marinda [4]). (c) Mortality risk ratio at 24 months between HEU and HUU children. (d) Mortality risk
ratio at 24 months between HEU and HUU children (excluding Marinda [4]).
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HUU infants [36]. As shown in Figure 3a, the difference
in pooled mortality of HEU and HUU infants at
12 months did not reach statistical significance (RR: 1.9,
95% CI: 0.9–3.8), possibly due to lack of statistical
power and high underlying mortality for all children. The
pooled estimate is again difficult to interpret in the pres-
ence of extremely high heterogeneity (I2 = 93%). The
study by Marinda et al. [4] provides outlying results, and
given the risk of classification bias in this study, we ran a
separate analysis excluding it. The pooled RR estimate
from the three remaining studies was 1.4 (95% CI:
1.0–1.8), indicating that HEU infants were likely to be at
increased risk. There was no heterogeneity of study
results (I2 = 14%) in this additional analysis (Figure 3b).
Figure 3c shows the result of the pooled analysis on
comparative mortality risk at 24 months in HEU and
HUU children. We included three cohort studies, compris-
ing 3938 HEU and 12 530 HUU children [4–6]. In the
study of Brahmbatt et al. [5] and Marinda et al., [4] no
mothers benefitted from maternal ART, whereas Shapiro’s
study included some women on ART. Also noteworthy
was that all HEU children in Shapiro’s study were breast-
fed for a median of 6 months while information on feed-
ing modality was not available in the other two papers.
The pooled estimate indicated that the mortality of HEU
children was more than double that of HUU children at
24 months of age (RR: 2.4, 95% CI: 1.1–5.1). The level
of heterogeneity was extremely high (I2 = 93%). As previ-
ously, we ran a separate analysis to address the risk of
classification bias in Marinda’s study. In this additional
analysis, the difference between the groups did not reach
statistical significance (RR: 2.0, 95% CI: 0.6–6.5) (Fig-
ure 3d). However, the removal of Marinda’s study caused
a substantial reduction of sample size, leading to a very
large uncertainty interval. The residual heterogeneity still
remained relatively high (I2 = 66%).
Factors associated with increased mortality risk of HEU
children
Given the diversity of definitions of variables and hetero-
geneity across studies, a narrative summary was consid-
ered appropriate. The following synthesis focused on
direction of the association between different factors and
the mortality outcome in HEU children. We identified 13
articles reporting the factors associated with the risk of
mortality among HEU children.
Maternal death and ill health
Maternal death significantly affects survival of uninfected
children. However, the data are limited to the time when
maternal ART was not available. In a large observational
cohort in Zimbabwe, Marinda et al. [4] reported that
HEU children whose mother had died were 2.7 times more
likely to die (95% CI: 1.9–3.9) than those whose mothers
survived. The pooled analysis of seven randomised trials
in sub-Saharan Africa also identified a strong effect of
maternal death (adjusted odds ratio: 3.7, 95% CI:
1.9–7.0) on child mortality [15]. A significant association
was also found in Zambia where hazard of death of HEU
infants through 4 months of age was 16.2 times higher
when the mother died within 4 months after delivery,
after allowing for maternal CD4 counts, haemoglobin
level and infant birthweight [23]. There is some evidence
to suggest that the time of death of the mother impacts on
the risk of death of her uninfected infant: Zaba et al. [38]
reported that the mortality risk was tripled in the 2 years
centring around the mother’s death, irrespective of her
HIV status.
The overall health status of mothers also plays a major
role in the survival of uninfected infants. Reduced care or
breastfeeding cessation as a result of maternal ill health
or increased exposure to infectious pathogens in the
households could explain increased risk of death of their
uninfected infants [4, 9]. However, the definition of poor
health and the indicators used varied between studies.
Taha et al. [7] used maternal HIV clinical stage as an
indicator to predict the risk of death in HEU infants and
found a 1.8-fold increase in the hazard of death [adjusted
hazard ratio (aHR): 1.8, 95% CI: 1.2–2.7] in children
aged 6–15 months with mothers at advanced disease
stage (3 or 4). A study in Tanzania also found an associa-
tion of a borderline statistical significance (HR: 1.5, 95%
CI: 1.0–2.3) between the mortality through 24 months
and advanced maternal HIV stage (defined as WHO dis-
ease stage 2 or higher) [27]. In this study, higher mater-
nal viral load at delivery (≥50 000 copies/ml) was
associated with a sevenfold (95% CI: 2.4–23.7) increase
of mortality hazard through 24 months of age in HEU
children. Several studies have shown the association
between low maternal haemoglobin level and increased
child mortality risk: Kuhn et al. [23] reported that a
maternal haemoglobin level <10 g/dl was significantly
associated with HEU infant mortality through 4 months
of age (aHR: 2.4, 95% CI: 1.1–5.4). Marinda et al. [4]
also found that HEU infants with mothers with haemo-
globin <70 g/dl were at 3.8 times higher risk of dying
than those of mothers with haemoglobin above the
threshold (95% CI: 2.1–7.0). Such an association was
however not found in HEU children aged up to
24 months in Tanzania when the risk of death was com-
pared between those with maternal haemoglobin below
and above 8.5 g/dl [27].
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Studies have shown mixed results with regard to the
impacts of maternal CD4 counts. Kuhn et al. [23] found
in Zambia that HEU infants born to mothers with CD4
cell counts <350 cells/ll were significantly more likely
to die during the first 4 months, after adjusting for
maternal death and low birthweight (HR: 2.9 with 95%
CI: 1.0–8.0). Further analysis on the same population
confirmed this association through 18 months of life:
the mortality hazard in children with mothers having
low CD counts (<200 cells/ll) was 3.2 times higher
(95% CI: 1.3–8.1) than in those with higher maternal
CD4 counts (>500 cells/ll) [39]. Similar results were
put forward by a study in Zimbabwe: HEU children
born to mothers with CD4 count <200/ll were at 2.6
higher risk of dying than those born to mothers with
CD4 counts ≥400/ll (95% CI: 1.8–3.8), allowing for
infant’s birthweight, sex, mother’s marital status and
household income [4]. A pooled analysis of seven ran-
domised trials in sub-Saharan Africa showed that risk
of death among HEU infants was 1.7 times higher when
maternal CD4 counts were <200/ll compared to when
they were above 500/ll, although the result did not
reach statistical significance [15]. Similarly, no signifi-
cant effects of maternal CD4 counts during pregnancy
on the mortality of HEU infants through 48 weeks were
observed in the Antiretrovirals and Nutrition (BAN)
clinical trial in Malawi [30].
Infant feeding practices
Our literature review revealed complexity of the issues
related to infant feeding, with inconsistent results between
studies suggesting that findings may be context-specific.
Some studies showed that type and duration of infant
feeding was associated with the risk of death among HEU
infants. Data from the Kesho Bora trial showed that never
breastfed infants or early weaned infants were seven times
more likely to die within 6 months after birth than infants
still being breastfed, after controlling for confounders
including infant’s HIV infections status (95% CI: 2.5–
17.9) [8]. Similar findings were put forward in a study in
Malawi: analysing cumulative mortality at 6–15 months
of age, Taha et al. [7] found that the mortality rate at
15 months was nearly double in never breastfed or early
weaned HEU infants as that of infants breastfed for long
durations (P = 0.04). The study has suggested long-term
adverse impacts of early weaning given that this difference
became significant only after 12 months of age [7]. Kour-
tis et al. [30] further highlighted that the mortality of
HEU infants increased after 28 weeks of age, the timing
of which corresponds with weaning from breastmilk for
the majority of infants in the cohort.
However, a comparative study of two trials in Uganda
showed that overall all-cause infant mortality did not sta-
tistically significantly differ between the trial in which
HEU children were weaned earlier (median 4 months)
and the trial with later weaning (median 9 months) [24].
In urban South Africa, infant feeding modality was not
associated with increased risk of mortality at 3 months
of age among HEU infants; mothers in this study had
fairly good access to safe replacement feeding including
clean water and infant formula [33]. An absence of sig-
nificant associations between infant feeding modality and
mortality risk was also reported by the pooled analysis of
seven PMTCT trials in sub-Saharan Africa [15]. Early
cessation of breastfeeding (i.e. before 4 months) was not
significantly associated with the hazard of death among
HEU infants in an observational cohort in Malawi after
adjusting for other covariates including maternal CD4
counts and vital status [23].
Low birthweight
Data from a randomised trial in Tanzania showed that
low birthweight was significantly associated with neona-
tal and post-neonatal mortality among HEU infants [35],
which confirms the findings of the multisite pooled analy-
sis in sub-Saharan Africa [15] and those of an observa-
tional cohort in Zambia [23]. Retrospective analysis of a
cohort study in Kenya further revealed that low birth-
weight was associated with a 3.3-fold increased hazard of
dying among HEU infants after adjusting for maternal
viral load (95% CI: 1.1–10.0) [40]. However, it may be
difficult to distinguish low birthweight from preterm
appropriate for gestational age and to assess its effects
from other factors including breastfeeding.
Discussion
HEU infants and children are at increased risk of mortal-
ity, although the differences between HEU and HUU
were statistically significant only for the estimate at
24 months. Our pooled estimates on cumulative mortal-
ity of HEU at 3, 6, 12 and 24 months of age were 2.0%,
3.6%, 5.5% to 11.0%, respectively. Our estimates are
comparable with previous results of a pooled analysis of
seven PMTCT trials in sub-Saharan Africa in the pre-
ART era in which the mortality estimates in HEU chil-
dren were 4.9% at 12 months and 7.6% at 24 months
[15]. Compared to the WHO estimates of infant mortal-
ity in the sub-Saharan region in 2013 (61/1000 live
births) [35], our estimate at 12 months is similar, sug-
gesting that HEU infants may not be at increased risk
compared to the general population. Compared to HUU,
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estimated relative mortality in HEU children at
12 months of age is nearly double, although the differ-
ence does not reach statistical significance; at 24 months
of age, there is a statistically significant doubling in risk
between the two groups but statistical significance is lost
once the study with bias concerns is removed [4]. All four
studies contributing to the pooled estimate of relative risk
at 12 months were from the pre-ART era [4, 5, 28, 36].
For 24 months of age, only one [6] of three studies [4, 5]
had data on mothers on ART.
The strength of our review lies in the systematic identifi-
cation and analysis of studies, with no restrictions on study
design and geographical locations; this enabled us to anal-
yse 14 articles, mostly from the pre-ART era, with mortality
data on HEU infants and 13 articles reporting on associated
factors. The quality and potential bias of included studies
were adequately addressed, which gave important consider-
ation to the interpretation of pooled estimates.
The major limitation is the heterogeneity of study
results. The pooled estimates are useful as they provide a
summary of what is published so far on the mortality risk
of HEU infants at different ages. Nevertheless, our results
must be interpreted with caution due to substantial
heterogeneity, with the value of I2 statistics ranging from
60% to 95%. Our effort to remove the studies with out-
lying results made little difference and residual hetero-
geneity persisted. Factors that may explain such high
heterogeneity include inconsistency in the coverage of
maternal ART and PMTCT prophylaxis in the studied
populations. While our meta-analyses used data mostly
from studies conducted before the widespread use of
ART, two studies included some women already benefit-
ing from ART [6, 32] and another two included women
randomised to receive ART until cessation of breastfeed-
ing at 6 months post-partum [26, 30]. As highlighted in
our qualitative review, maternal survival and health sig-
nificantly improve survival probability of their uninfected
infants. The association between mortality and duration
of breastfeeding is also reported by the reviewed litera-
ture. Maternal ART, whether for mother’s own health or
to ensure appropriate nutritional or immunological bene-
fits for infants through breastfeeding, is very likely to
impact on the mortality of HEU infants. Two studies
demonstrate either a direct association between ART and
improved under-5 mortality of all infants [42] or the
importance of ART availability with ecological associa-
tion between maternal survival and reduced mortality of
infants younger than 2 years [43]. Due to lack of infor-
mation, we were unable to assess the contribution of
maternal exposure to ART to overall heterogeneity in the
pooled estimates. The evidence regarding maternal sur-
vival and infant feeding in relation to the mortality of
HEU children needs to be substantiated in the post-ART
era. Another possible source of heterogeneity is children’s
different exposure to cotrimoxazole prophylaxis, which
may have survival benefits [4, 25, 30]. The mortality
risks in the study of Chilongozi might have been
underestimated as the children were routinely given cotri-
moxazole. Children in three other studies [29–31] also
were given cotrimoxazole, but details of coverage were
unknown, excluding subgroup analyses by cotrimoxazole
exposure. Finally, heterogeneity related to context-specific
factors, such as background mortality and access to
health care, may have been important.
Conclusion
As the use of maternal ART expands, the number of HEU
infants continues to increase globally. We need a better
understanding of the risks faced by this vulnerable group.
Our results suggest that early mortality of HEU infants
might not be significantly different from that of general
population or HUU infants living in the same community
but may become significant when considering the overall
period to 2 years of age. However, heterogeneity between
studies and lack of high-quality data comparing the mortal-
ity of HEU and HUU infants limits interpretation of the
pooled estimates. More data from the post-ART era are
needed to understand the impact of maternal health on
breastfeeding and on the survival of HEU infants. Further
research is needed to inform more precise estimates of
HEU infant mortality and to identify strategic interventions
to reduce mortality risks in this vulnerable population.
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